Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | LGALS9 | O00182 | 1/20 | 0.45 |
| ▸ | LGALS1 | P09382 | 1/20 | 0.45 |
| ▸ | LGALS3 | P17931 | 1/20 | 0.45 |
| ▸ | LGALS7; LGALS7B | P47929 | 1/20 | 0.45 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | SLC28A3 | Q9HAS3 | 2/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25333021 | 1.00 | ALDH1A1 (0.46) | ALDH1A1LGALS9LGALS1LGALS3LGALS7; LGALS7B | |
| SCHEMBL29993128 | 1.00 | ALDH1A1 (0.46) | ALDH1A1LGALS9LGALS1LGALS3LGALS7; LGALS7B | |
| SCHEMBL21828727 | 1.00 | ALDH1A1 (0.46) | ALDH1A1LGALS9LGALS1LGALS3LGALS7; LGALS7B | |
| SCHEMBL25387949 | 1.00 | ALDH1A1 (0.46) | ALDH1A1LGALS9LGALS1LGALS3LGALS7; LGALS7B | |
| Niacinamide SCHEMBL28136690 | 0.85 | F7 (0.51) | ALDH1A1MAOBSLC28A3 | |
| Niacinamide SCHEMBL17315028 | 0.84 | F7 (0.50) | ALDH1A1LGALS9LGALS1LGALS3LGALS7; LGALS7B | |
| SCHEMBL19717962 | 0.84 | LGALS9 (0.46) | LGALS9LGALS1LGALS3LGALS7; LGALS7BMAOB | |
| SCHEMBL6570199 | 0.84 | LGALS9 (0.61) | LGALS9LGALS1LGALS3LGALS7; LGALS7BMAOB | |
| SCHEMBL7141014 | 0.84 | LGALS9 (0.61) | LGALS9LGALS1LGALS3LGALS7; LGALS7BMAOB | |
| SCHEMBL6570202 | 0.84 | LGALS9 (0.61) | LGALS9LGALS1LGALS3LGALS7; LGALS7BMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 243 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11865127-B2 | Composition comprising ketone body and nicotinamide adenine dinucleotide modulator and methyl donor | TECTON GROUP, LLC (US) | 2024-01-09 | — | — | US | claimed |
| US-20220133755-A1 | COMPOSITION COMPRISING KETONE BODY AND NICOTINAMIDE ADENINE DINUCLEOTIDE MODULATOR AND METHYL DONOR | TECTON BG, INC. | 2022-05-05 | — | — | US | claimed |
| US-11202790-B2 | Composition comprising ketone body and nicotinamide adenine dinucleotide modulator and methyl donor | TECTON GROUP, LLC (US) | 2021-12-21 | — | — | US | claimed |
| CN-113727987-A | Use of nicotinamide riboside, nicotinic acid riboside, reduced nicotinoyl riboside compound and nicotinoyl riboside compound derivative in preparation of articles | 可劳迈戴斯有限公司 | 2021-11-30 | — | — | CN | claimed |
| US-10927101-B2 | Neopetrosides A and B, and synthesis method thereof | INJE UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) | 2021-02-23 | — | — | US | claimed |
| US-20210030774-A1 | COMPOSITION COMPRISING KETONE BODY AND NICOTINAMIDE ADENINE DINUCLEOTIDE MODULATOR AND METHYL DONOR | TECTON BG, INC. | 2021-02-04 | — | — | US | claimed |
| US-10688115-B2 | Composition comprising ketone body and nicotinamide adenine dinucleotide modulator and methyl donor | TECTON GROUP, LLC (US) | 2020-06-23 | — | — | US | claimed |
| US-10456411-B2 | Composition comprising ketone body and nicotinamide adenine dinucleotide modulator and methyl donor | TECTON GROUP, LLC (US) | 2019-10-29 | — | — | US | claimed |
| US-20190290666-A1 | COMPOSITION COMPRISING KETONE BODY AND NICOTINAMIDE ADENINE DINUCLEOTIDE MODULATOR AND METHYL DONOR | TECTON BG, INC. | 2019-09-26 | — | — | US | claimed |
| US-10376528-B2 | Composition comprising ketone body and nicotinamide adenine dinucleotide modulator and methyl donor | TECTON GROUP, LLC (US) | 2019-08-13 | — | — | US | claimed |
| US-20190218206-A1 | NEOPETROSIDES A AND B, AND SYNTHESIS METHOD THEREOF | INJE UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) | 2019-07-18 | — | — | US | claimed |
| US-20180256612-A1 | Composition Comprising Ketone Body and Nicotinamide Adenine Dinucleotide Modulator and Methyl Donor | THORNE RESEARCH, INC. (US) | 2018-09-13 | — | — | US | claimed |
| US-20260062436-A1 | METHODS OF PREPARING REDUCED NICOTINAMIDE RIBOSIDE AND DERIVATIVES THEREOF | THE QUEEN'S UNIVERSITY OF BELFAST (GB) | 2026-03-05 | — | — | US | disclosed |
| EP-4472948-A4 | NICOTINATE AND NICOTINAMIDE RIBOSIDE-BASED COMPOUNDS AND DERIVATIVES THEREOF | NEW FRONTIER BIO INC (US) | 2026-01-21 | — | — | EP | disclosed |
| US-20250289840-A1 | RNA STABILIZING SUBSTANCES AND METHODS OF USE | TEAM MEDICAL, LLC | 2025-09-18 | — | — | US | disclosed |
| EP-3322419-B1 | SYNTHESES, ACTIVITIES, AND METHODS OF USE OF DIHYDRONICOTINAMIDE RIBOSIDE DERIVATIVES | UNIV CORNELL (US) | 2025-09-03 | — | — | EP | disclosed |
| EP-1468698-A2 | HUMAN QUINONE REDUCTASE 2 CONJUGATES FOR ADEPT AND GDEPT | ENZACTA R & D LIMITED (GB) | 2004-10-20 | — | — | EP | disclosed |
| US-20030086933-A1 | Therapeutic systems | ENZACTA R & D LIMITED | 2003-05-08 | — | — | US | disclosed |
| EP-0988059-A2 | HUMAN QUINONE REDUCTASE 2 CONJUGATES FOR ADEPT AND GDEPT | ENZACTA R & D LIMITED (GB) | 2000-03-29 | — | — | EP | disclosed |
| WO-1998057662-A2 | THERAPEUTIC SYSTEMS | ENZACTA R & D LIMITED (GB) | 1998-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11202790-B2 | Composition comprising ketone body and nicotinamide adenine dinucleotide modulator and methyl donor | NNMT, NNT, NADK | ALDH1A1 814/4885LGALS9 3708/4885LGALS1 3074/4885 |
| US-10456411-B2 | Composition comprising ketone body and nicotinamide adenine dinucleotide modulator and methyl donor | NNMT, NNT, NADK | ALDH1A1 814/4885LGALS9 3708/4885LGALS1 3074/4885 |
| US-20260062436-A1 | METHODS OF PREPARING REDUCED NICOTINAMIDE RIBOSIDE AND DERIVATIVES THEREOF | NNT, SIRT1, NAMPT | ALDH1A1 627/4885LGALS9 3888/4885LGALS1 3850/4885 |
| US-20180256612-A1 | Composition Comprising Ketone Body and Nicotinamide Adenine Dinucleotide Modulator and Methyl Donor | NNMT, NNT, NADK | ALDH1A1 814/4885LGALS9 3708/4885LGALS1 3074/4885 |
| US-20210030774-A1 | COMPOSITION COMPRISING KETONE BODY AND NICOTINAMIDE ADENINE DINUCLEOTIDE MODULATOR AND METHYL DONOR | NNMT, NNT, NADK | ALDH1A1 814/4885LGALS9 3708/4885LGALS1 3074/4885 |
| US-10688115-B2 | Composition comprising ketone body and nicotinamide adenine dinucleotide modulator and methyl donor | NNMT, NNT, NADK | ALDH1A1 814/4885LGALS9 3708/4885LGALS1 3074/4885 |
| US-10376528-B2 | Composition comprising ketone body and nicotinamide adenine dinucleotide modulator and methyl donor | NNMT, NNT, NADK | ALDH1A1 814/4885LGALS9 3708/4885LGALS1 3074/4885 |
| US-20220133755-A1 | COMPOSITION COMPRISING KETONE BODY AND NICOTINAMIDE ADENINE DINUCLEOTIDE MODULATOR AND METHYL DONOR | NNMT, NNT, NADK | ALDH1A1 814/4885LGALS9 3708/4885LGALS1 3074/4885 |
| US-11865127-B2 | Composition comprising ketone body and nicotinamide adenine dinucleotide modulator and methyl donor | NNMT, NNT, NADK | ALDH1A1 814/4885LGALS9 3708/4885LGALS1 3074/4885 |
| US-20190290666-A1 | COMPOSITION COMPRISING KETONE BODY AND NICOTINAMIDE ADENINE DINUCLEOTIDE MODULATOR AND METHYL DONOR | NNMT, NNT, NADK | ALDH1A1 814/4885LGALS9 3708/4885LGALS1 3074/4885 |
| US-20190218206-A1 | NEOPETROSIDES A AND B, AND SYNTHESIS METHOD THEREOF | NPPA, NME4, PINK1 | ALDH1A1 3266/4885LGALS9 4061/4885LGALS1 3853/4885 |
| US-20030086933-A1 | Therapeutic systems | NQO2, NQO1, NAPRT | ALDH1A1 1498/4885LGALS9 4826/4885LGALS1 4880/4885 |
| US-20250289840-A1 | RNA STABILIZING SUBSTANCES AND METHODS OF USE | SYNCRIP, SNRPA, RNASE1 | ALDH1A1 1153/4885LGALS9 904/4885LGALS1 693/4885 |
| US-10927101-B2 | Neopetrosides A and B, and synthesis method thereof | NPPA, NME4, PINK1 | ALDH1A1 3266/4885LGALS9 4061/4885LGALS1 3853/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.